Re: Don't look now but...
|
5
|
Resverlogix Corp.
|
May 08, 2019 10:56AM
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
3
|
Resverlogix Corp.
|
Oct 16, 2018 05:07PM
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
1
|
Resverlogix Corp.
|
Oct 16, 2018 06:57PM
|
Re: HDL Functionality
|
2
|
Resverlogix Corp.
|
May 08, 2019 05:03PM
|
Re: HDL Functionality
|
2
|
Resverlogix Corp.
|
May 08, 2019 05:27PM
|
Re: HDL Functionality
|
3
|
Resverlogix Corp.
|
May 08, 2019 05:32PM
|
Re: HDL Functionality
|
3
|
Resverlogix Corp.
|
May 06, 2019 10:49AM
|
Re: HDL Functionality
|
3
|
Resverlogix Corp.
|
May 09, 2019 07:09PM
|
Re: Insider Selling
|
4
|
Resverlogix Corp.
|
Jul 13, 2019 09:06PM
|
Re: Insider Selling
|
|
Resverlogix Corp.
|
Jul 11, 2019 08:44PM
|
Re: Insider Selling
|
4
|
Resverlogix Corp.
|
Jul 11, 2019 09:17PM
|
Re: Inverted Hammer
|
1
|
Resverlogix Corp.
|
Nov 15, 2018 12:19PM
|
Re: J&J Abiraterone going generic
|
2
|
Zenith Epigenetics
|
Nov 21, 2018 03:48PM
|
Re: Kudos to Dr. Kausik Ray
|
1
|
Resverlogix Corp.
|
Mar 13, 2019 07:36PM
|
Re: Last hour.....
|
1
|
Resverlogix Corp.
|
May 31, 2019 03:48PM
|
Re: Last hour.....
|
4
|
Resverlogix Corp.
|
Jun 01, 2019 01:51AM
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
6
|
Zenith Epigenetics
|
Nov 22, 2018 01:42PM
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 03, 2018 01:02PM
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 06:16AM
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 08:24AM
|